Trending Content - Investment Banking Forum
| +182 | UBS Accused of Favoring H-1B Workers While Cutting U.S.-Born Employees | 44 | 1h |
| +77 | IB Energy Drink Tier List / Ranking | 52 | 1h |
| +70 | PJT M&A Group Selection 2026 | 13 | 5h |
| +36 | Quick Thoughts on CVC AI Sale Process | 7 | 3d |
| +33 | Feedback for internship first desk at IBD BB - personal fit, "don't be too confident" | 23 | 20h |
| +27 | Does BofA still pay its associates rat pellets? | 11 | 3h |
| +24 | ONLY THESE BANKS OR YOU STRUCK OUT | 6 | 7m |
| +19 | Updated JPM Group Rankings | 28 | 2h |
| +18 | What happened to Greenhill | 8 | 3d |
| +18 | VP Deal Origination Credit | 2 | 4h |
Career Resources
Guggenheim has been actively growing its investment banking practice, bringing in numerous senior MDs from other banks. However, despite this growth, the platform is still relatively new and doesn't yet match the deal flow of bulge brackets or more established elite boutiques. This has historically impacted their exit opportunities, particularly for mega-fund private equity roles, though some top analysts have managed strong exits to firms like Lazard, Evercore, Moelis, and Centerview.
Recently, there have been notable movements of senior MDs leaving Guggenheim for other firms like Barclays and UBS. This could be attributed to several factors, including the firm's evolving platform, group-specific deal flow, and the competitive nature of the industry. While Guggenheim is respected for its technical experience and growing reputation, it may still face challenges in retaining top talent as it continues to establish itself in the market.
Sources: Barclays vs Guggenheim IBD (New York), Wall Street Is Undergoing A Hiring Sea Change That Could Take It Back 30 Years, Guggenheim Partners Investment Banking, Barclays MDs leaving, What's going on in Citi Houston??
Bumping, interesting question with the recent larger than normal layoff. See they lost a strong industrials Md to WF last year, a sports MD in their media group recently left to Lazard, and a few people in their biopharma jumped ship to Leerink Partners.
Seems a bit concerning, but at the same time there always seems to be some turnover at banks. Curious if anyone has any insight.
Velit ut aliquid consequatur suscipit dolorem numquam ab. Repudiandae nihil assumenda eos. Eum inventore exercitationem consequatur qui.
Dolor quibusdam aliquam ipsa corrupti architecto. Nulla voluptatum velit accusamus dolorum.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...